Summary
Osteoporosis is the most common reason for broken bones among elderly women. In the European Union, annual direct medical costs of fractures attributed to osteoporosis reach €36bn and are expected to rise to €76.9bn by 2050 in pace with the aging of population.
Early diagnosis and prevention is the key to reducing this burden and deliver more efficient health care to European citizens with new tools for doctors to better serve their patients.
Our mission at BONE VITAE (www.bonevitae.pl, Wroclaw, Poland) is to implement fast in-practice medical screening for early flags of osteoporosis with our patented osteoscanner ICT platform, the new frontline of prevention. Our non-invasive and painless bio-impedance spectroscopy technology is the only one that provides data on bone composition and chemical changes that mark the very start of osteoporosis onset, when there is still time to prevent it.
The Multi-electrode Osteoporosis Detection Device (MOsteoDD) platform is an exciting market opportunity for our company, a small, highly innovative venture with a powerful patented core technology seeking to enter the growth market of osteoporosis diagnostics worth $6–7 billion a year globally. Our patented six-electrode setup provides 95+% diagnostic accuracy results in less than 40 seconds, while the platform’s web service will analyse the device output and generate a written report for doctor’s use allowing pre-diagnosed patients to be referred for further scanning (DEXA) or for prescriptions to be issued.
The first version of the MOsteoDD osteoscanner has clinical validation in Poland and the CE mark (Conformité Européenne), and is currently at Minimum Viable Product (MVP) stage at Technology Readiness Level (TRL) 8. Current efforts are directed at maturing the platform to specific customer needs to reach the market with the support of SMEI funding.
Early diagnosis and prevention is the key to reducing this burden and deliver more efficient health care to European citizens with new tools for doctors to better serve their patients.
Our mission at BONE VITAE (www.bonevitae.pl, Wroclaw, Poland) is to implement fast in-practice medical screening for early flags of osteoporosis with our patented osteoscanner ICT platform, the new frontline of prevention. Our non-invasive and painless bio-impedance spectroscopy technology is the only one that provides data on bone composition and chemical changes that mark the very start of osteoporosis onset, when there is still time to prevent it.
The Multi-electrode Osteoporosis Detection Device (MOsteoDD) platform is an exciting market opportunity for our company, a small, highly innovative venture with a powerful patented core technology seeking to enter the growth market of osteoporosis diagnostics worth $6–7 billion a year globally. Our patented six-electrode setup provides 95+% diagnostic accuracy results in less than 40 seconds, while the platform’s web service will analyse the device output and generate a written report for doctor’s use allowing pre-diagnosed patients to be referred for further scanning (DEXA) or for prescriptions to be issued.
The first version of the MOsteoDD osteoscanner has clinical validation in Poland and the CE mark (Conformité Européenne), and is currently at Minimum Viable Product (MVP) stage at Technology Readiness Level (TRL) 8. Current efforts are directed at maturing the platform to specific customer needs to reach the market with the support of SMEI funding.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/728824 |
| Start date: | 01-07-2016 |
| End date: | 30-09-2016 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Osteoporosis is the most common reason for broken bones among elderly women. In the European Union, annual direct medical costs of fractures attributed to osteoporosis reach €36bn and are expected to rise to €76.9bn by 2050 in pace with the aging of population.Early diagnosis and prevention is the key to reducing this burden and deliver more efficient health care to European citizens with new tools for doctors to better serve their patients.
Our mission at BONE VITAE (www.bonevitae.pl, Wroclaw, Poland) is to implement fast in-practice medical screening for early flags of osteoporosis with our patented osteoscanner ICT platform, the new frontline of prevention. Our non-invasive and painless bio-impedance spectroscopy technology is the only one that provides data on bone composition and chemical changes that mark the very start of osteoporosis onset, when there is still time to prevent it.
The Multi-electrode Osteoporosis Detection Device (MOsteoDD) platform is an exciting market opportunity for our company, a small, highly innovative venture with a powerful patented core technology seeking to enter the growth market of osteoporosis diagnostics worth $6–7 billion a year globally. Our patented six-electrode setup provides 95+% diagnostic accuracy results in less than 40 seconds, while the platform’s web service will analyse the device output and generate a written report for doctor’s use allowing pre-diagnosed patients to be referred for further scanning (DEXA) or for prescriptions to be issued.
The first version of the MOsteoDD osteoscanner has clinical validation in Poland and the CE mark (Conformité Européenne), and is currently at Minimum Viable Product (MVP) stage at Technology Readiness Level (TRL) 8. Current efforts are directed at maturing the platform to specific customer needs to reach the market with the support of SMEI funding.
Status
CLOSEDCall topic
SMEInst-06-2016-2017Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
